• MustGrow outlined a push to scale mustard-derived biological inputs across biofertility and biocontrol as synthetic pesticide restrictions tighten globally.
• TerraSante biofertility sales ramp began in 2025; current production capacity about 650 tonnes, tied to potential USD 16 million revenue.
• Actionable capacity expansion targeted at about 2,000-3,900 tonnes, implying potential USD 50-100 million revenue with gross margin estimates of 40-60%.
• TerraMG biocontrol registrations targeted for 2026/2027 in Canada and the US; Bayer holds an exclusive EMEA license with milestone payments and future royalties.
• Capital structure: 62,959,818 shares outstanding, 76,679,556 fully diluted; market cap CAD 35 million; cash CAD 419,577; debt CAD 417,991.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MustGrow Biologics Corp. published the original content used to generate this news brief on June 02, 2026, and is solely responsible for the information contained therein.